Welcome to our dedicated page for Wellgistics Health news (Ticker: WGRX), a resource for investors and traders seeking the latest updates and insights on Wellgistics Health stock.
Wellgistics Health, Inc. (NASDAQ: WGRX) generates news at the intersection of pharmacy distribution, health information technology, artificial intelligence, and blockchain-enabled smart contracts. Company announcements highlight how its integrated platform connects more than 6,500 pharmacies and over 200 manufacturers, combining wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Recent news has focused on the rollout and evolution of the EinsteinRx™ pharmacy dispensing optimization AI platform, including its integration into pharmacy point-of-sale systems and its role as a prescription management hub. Updates also cover the development of the PharmacyChain™ blockchain-enabled smart contracts platform, supported by a license agreement with DataVault AI Inc. and the use of tokenization and quantum key encryption to create secure digital twins of pharmacy processes and transactions.
Investors and industry observers can follow coverage of therapeutic and product initiatives such as the commercial launch of the diabetes drug Brenzavvy® through the Wellgistics Pharmacy Network, distribution of GLP-1 companion muscle loss medical foods with Tollo Health, and offerings related to Long COVID, including Galectovid™ and Tollovid®. News items also address corporate developments like letters of intent for acquisitions, sponsorship of Dream Bowl 2026 and related meme coin distributions, financial results, and Nasdaq listing compliance updates.
This news feed aggregates these disclosures so readers can review earnings-related releases, product and partnership announcements, regulatory filings referenced in press releases, and strategic updates about Wellgistics Health’s role in the U.S. prescription drug and wellness markets. Regularly reviewing this page can help users understand how the company’s AI, blockchain, and distribution capabilities are being applied across its pharmacy network and manufacturer relationships.
Wellgistics Health (NASDAQ:WGRX) signed a non-exclusive, non-binding $105,000,000 Letter of Intent dated March 23, 2026 to evaluate a potential all-stock acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.
The proposed deal aims to expand Wellgistics' pharmacy distribution and AI-driven patient access platform by adding research and drug-development capabilities; it remains subject to due diligence, definitive agreements, board approvals, and customary closing conditions with no assurance of completion.
Wellgistics (NASDAQ:WGRX) announced that its President and Interim CEO Prashant Patel and one board participant converted approximately $2.0 million of accrued compensation into common stock at $0.20 per share, resulting in issuance of ~10,000,000 shares.
The company also issued 10,000,000 warrants exercisable at $0.01 for five years, and the converted shares are subject to a 6-month lock-up. The board approved the conversion to align management incentives with long-term shareholder value.
Wellgistics (NASDAQ:WGRX) said its President & Interim-CEO outlined a strategic pivot toward selling prescription drugs directly to patients via its online pharmacy and expanding its EinsteinRx AI platform beyond dispensing optimization.
The company cited exclusive technology licensing for PharmacyChain™, partnerships including NFL Alumni Health and Tollo Health, and plans to deploy telemedicine, diagnostic testing, and benefits-verification tools.
Wellgistics (NASDAQ:WGRX) secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV), making the service available immediately via its EinsteinRx AI hub and preparing integration into PharmacyChain later in 2026.
Management expects EBV to contribute to a new revenue stream beginning in Q2 2026 and highlights cost reductions for its own pharmacy as it rolls out GLP-1 and Forzet weight-loss offerings. The EBV market is cited at $2.39B in 2025 growing to $3.0B by 2030.
Wellgistics Health (NASDAQ:WGRX) launched Forzet, a medical food for the dietary management of muscle loss associated with GLP-1 agonist weight-loss therapies, on March 9, 2026. Forzet is OTC, not an FDA-approved drug, and was evaluated in multiple controlled clinical studies in Europe.
The company will distribute Forzet through its affiliated pharmacy and select Wellgistics Pharmacy Network members and plans to promote it via EinsteinRx™ point-of-sale pop-ups and expanded DTC telehealth/pharmacy channels.
Wellgistics Health (NASDAQ:WGRX) selected Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum/Besu and Corda (R3) to begin building its patented PharmacyChain™ smart contracts pharmaceutical tracking system to support serialization mandates such as the DSCSA.
The company plans closed-loop HIPAA-compliant development and expects initial operation within its own pharmacy by the end of Q2 2026, with intent to roll out to 6,500+ independent pharmacies later in 2026. Wellgistics cites exclusive IP licensed from Datavault AI and highlights large addressable markets, including a $634 billion U.S. prescription drug market projected to $883 billion by 2030.
Datavault AI (NASDAQ:DVLT) and Wellgistics Health plan to expand a blockchain smart-contracts partnership to support Healthcare as a Service (HaaS) integration.
The deal adds Datavault AI intellectual property to enable tokenized patient data, pharmacy fulfillment via Wellgistics Pharmacy, telemedicine links, and an updated iOS app for patient adoption.
Wellgistics Health (NASDAQ:WGRX) completed a strategic investment in a San Francisco mental health AI startup and is expanding patient‑engagement efforts tied to its EinsteinRx™ AI and PharmacyChain™ platform.
The move strengthens partnerships with Tollo Health and NFL Alumni Health, targets support for patients starting GLP‑1 therapy, and aligns with a mental health software TAM cited at $6.3 billion (2025) growing to $18.1 billion (2033).
Wellgistics Health (NASDAQ:WGRX) expanded its partnership with Tollo Health to add telehealth, a mental health AI app and broader digital services via TolloCare, a Tollo Health subsidiary. TolloCare will support GLP-1, Long COVID, weight-loss maintenance, cardiometabolic, sleep apnea and pain-management care and integrate telemedicine with pharmacy services.
The expansion includes a contracted telehealth platform with over 5,000 onboarded physicians and an agreement to deploy a stealth San Francisco Bay Area mental health AI app across TolloCare's patient base.
Wellgistics Health (NASDAQ:WGRX) announced an agreement with NFL Alumni Health on February 9, 2026 to deploy its EinsteinRx™ AI pharmacy hub and PharmacyChain™ smart contracts to improve care for former NFL players and rural communities.
The initiative will leverage the Wellgistics Pharmacy Network of 6,500 independent pharmacies and focus on mental health, weight loss, sleep apnea, cardiometabolic disease, pain management and Long COVID, with NFL Alumni Health Ambassadors supporting local outreach.